OmanDocSign in

Curriculum · Hematology

Warfarin over-anticoagulation and reversal

What it is

Warfarin works through the vitamin K dependent coagulation factors, which are factors II, VII, IX and X together with protein C and protein S. It inhibits the vitamin K epoxide reductase enzyme and so depletes those factors. Its onset of action is 24 to 72 hours, with a peak at 5 to 7 days, so it needs bridging. The half-life of warfarin is 40 hours.

How it is diagnosed

Monitoring of warfarin is by the INR.

How it is treated

The reversal agent for warfarin is vitamin K. Where reversal has to be urgent, prothrombin complex concentrate (PCC), such as octaplex, is the agent used. Warfarin is started under cover. The traditional route is a heparin drip then warfarin, with an INR of 2-3 and an overlap until the INR is therapeutic. LMWH such as enoxaparin is good for outpatient use but needs renal dosing, and the DOACs, rivaroxaban and apixaban, are easy to use with no monitoring but are not for severe renal failure or pregnancy.

A mechanical valve requires long term warfarin and has a longer half life, which makes it better for the younger patient and is what childbearing women and atrial fibrillation patients are given. The same page adds pregnant ladies to that, to avoid degeneration of the bioprosthetic valve in pregnancy, although warfarin has a low teratogenic risk. That sits against what is written elsewhere, that in pregnancy the anticoagulant is LMWH and warfarin is contraindicated, and both should be held in mind. A bioprosthetic valve is better for the elderly, and of these a heterograft takes warfarin for the first 3 months after replacement, with the aortic valve INR at 2-3 and the mitral valve INR at 2.5-3.5 written beside it, while a homograft does not require warfarin at all but has a shorter half life, 8-10 years. No INR is set for the mechanical valve on that page.

Where warfarin sits in pulmonary embolism is set out this way: patients with a PE should be commenced on anticoagulant therapy, either heparin or a low molecular weight heparin, followed by the commencement of warfarin. Haemodynamically unstable patients should be thrombolysed, with streptokinase or tissue plasminogen activator, and if there is a contraindication to thrombolysis the patient is referred to cardiothoracic surgery for consideration of thrombectomy. The supportive part is supplemental oxygen if hypoxaemic, IV fluids and vasopressors if there is no response to fluids, and morphine.